Yi Zheng, PhD

Director, Experimental Hematology and Cancer Biology

Institute Co-Director, Cancer and Blood Diseases Institute

Katherine Stewart Waters Endowed Chair

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-0595

Fax 513-636-3768

Email yi.zheng@cchmc.org

Using transgenic and gene targeted mouse models to study the physiological and pathological roles of Rho GTPases and their regulators in hematopoiesis, neurogenesis, lung cancer development and small intestinal stem cell regulations mechanism based, rational design of small molecule inhibitors targeting Rho GTPase signaling modules and pathologic functions in cancer and blood diseases; mouse model studies of mTor signaling function in hematopoietic stem cells and small intestinal stem cells.

Visit the Zheng Lab.

BS: Tsinghua University, Beijing, China, 1986.

MS: Cornell University, Ithaca, NY, 1988.

PhD: Cornell University, Ithaca, NY, 1991.

Postdoctoral Fellow: Cornell University, Ithaca, NY, 1995.

View All PubMed Publications

Maliken BD, Kanisicak O, Karch J, Khalil H, Fu X, Boyer JG, Prasad V, Zheng Y, Molkentin JD. Gata4-Dependent Differentiation of c-Kit+ Derived Endothelial Cells Underlies Artefactual Cardiomyocyte Regeneration in the Heart. Circulation. 2018 Apr 17.

Akbar H, Duan X, Piatt R, Saleem S, Davis AK, Tandon NN, Bergmeier W, Zheng Y. Small molecule targeting the Rac1-NOX2 interaction prevents collagen-related peptide and thrombin induced reactive oxygen species generation and platelet activation. J Thromb Haemost. 2018 Jul 14.

Liu W, Du W, Shang X, Wang L, Evelyn C, Florian MC, A Ryan M, Rayes A, Zhao X, Setchell K, Meller J, Guo F, Nassar N, Geiger H, Pang Q, Zheng Y. Rational identification of a Cdc42 inhibitor presents a new regimen for long-term hematopoietic stem cell mobilization. Leukemia. 2018 Sep 25.

Du W, Liu W, Mizukawa B, Shang X, Sipple J, Wunderlich M, Geiger H, Davies S, Mulloy J, Pang Q, Zheng Y. A non-myeloablative conditioning approach for long-term engraftment of human and mouse hematopoietic stem cells. Leukemia. 2018 Jun 29.

Grigoryan A, Guidi N, Senger K, Liehr T, Soller K, Marka G, Vollmer A, Markaki Y, Leonhardt H, Buske C, Lipka DB, Plass C, Zheng Y, Mulaw MA, Geiger H, Florian MC. LaminA/C regulates epigenetic and chromatin architecture changes upon aging of hematopoietic stem cells. Genome Biol. 2018 Nov 7;19(1):189.

Florian MC, Klose M, Sacma M, Jablanovic J, Knudson L, Nattamai KJ, Marka G, Vollmer A, Soller K, Sakk V, Cabezas-Wallscheid N, Zheng Y, Mulaw MA, Glauche I, Geiger H. Aging alters the epigenetic asymmetry of HSC division. PLoS Biol. 2018 Sep 20;16(9):e2003389.

Chadwick ML, Lane A, Thomas D, Smith AR, White AR, Davidson D, Feng Y, Boscolo E, Zheng Y, Adams DM, Gupta A, Veillette A, Chow LML. Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma. Oncotarget. 2018 May 15;9(37):24750-24765.

Yang JQ, Kalim KW, Li Y, Duan X, Nguyen P, Khurana Hershey GK, Kroner J, Ruff B, Li Z, Salomonis N, Rochman M, Wen T, Zheng Y, Guo F. Rational targeting Cdc42 restrains Th2 cell differentiation and prevents allergic airway inflammation. Clin Exp Allergy. 2018 Oct 11.

Hayashi Y, Zhang Y, Yokota A, Yan X, Liu J, Choi K, Li B, Sashida G, Peng Y, Xu Z, Huang R, Zhang L, Freudiger GM, Wang J, Dong Y, Zhou Y, Wang J, Wu L, Bu J, Chen A, Zhao X, Sun X, Chetal K, Olsson A, Watanabe M, Romick-Rosendale LE, Harada H, Shih LY, Tse W, Bridges JP, Caligiuri MA, Huang T, Zheng Y, Witte DP, Wang QF, Qu CK, Salomonis N, Grimes HL, Nimer SD, Xiao Z, Huang G. Pathobiologic Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes. Cancer Discov. 2018 Aug 23.

Nayak R, Hegde S, Althoff M, Wellendorf A, Mohmoud F, Perentesis J, Reina-Campos M, Reynaud D, Zheng Y, Diaz-meco M, Moscat J, Cancelas JA. The signaling axis atypical protein kinase C λ/ι-Satb2 mediates leukemic transformation of B-cell progenitors. Nature Communications. 2018.

Targeting Cdc42 for bone marrow transplant therapies. Principal investigator. National Institutes of Health. Apr 2015 - Apr 2020. NIH R01CA193350.

Cdc42, hematopoietic stem cell polarity and cell fate. Principal Investigator. National Institute of Health - NIDDK. Dec 2015 - Nov 2019.

Blood stem cell aging and biomarker studies. Co-Principal Investigator. National Institute of Health - NHLBI. Aug 2016 - July 2020.

Activated protein C peptides for radio-mitigation. Co-Principal Investigator. National Institute of Health - NIAID. Apr 2017 - Mar 2019.

Leukemia Stem cell polarity and differentiation therapy. Co-Principal Investigator. National Institute of Health - NCI. Sep 2017 - July 2022.

Targeting TET1 signaling to treat acute myeloid leukemia. Co-Investigator. National Institutes of Health. Jan 2017 - Dec 2021. R01CA211614.

Refrigerated preservation of platelets for human transfusion. Co-Principal Investigator. Ohio Third Frontier Fund. Feb 2018 - Jan 2019.